Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation

Blood

Volumn 119, Issue 12, 2012, Pages 2956-2959

  Hardy, Nancy M ^a   Fellowes, Vicki ^a   Rose, Jeremy J ^a   Odom, Jeanne ^a   Pittaluga, Stefania ^a   Steinberg, Seth M ^a   Blacklock Schuver, Bazetta ^a   Avila, Daniele N ^a   Memon, Sarfraz ^a   Kurlander, Roger J ^a   Khuu, Hahn M ^a   Stetler Stevenson, Maryalice ^a   Mena, Esther ^a   Dwyer, Andrew J ^b   Levine, Bruce L ^c   June, Carl H ^c   Reshef, Ran ^c   Vonderheide, Robert H ^c   Gress, Ronald E ^a   Fowler, Daniel H ^a   Hakim, Frances T ^a   Bishop, Michael R ^a,d   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR DERIVED DONOR LYMPHOCYTE;

EID: 84858814493     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-378398     Document Type: Article

References (18)

1. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2): 433-444. (Pubitemid 27074209)
2. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18(16):3031-3037. (Pubitemid 30648798)
3. Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(5):437-441. (Pubitemid 43115032)
4. Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol. 2008;21(2):205-222. (Pubitemid 351712713)
5. Fowler D, Hou J, Foley J, et al. Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. Cytotherapy. 2002;4(5):429-430. (Pubitemid 35375302)
6. Fowler DH, Odom D, Castro K, et al. Co-stimulated Th2 cells for modulation of acute GVHD: phase I clinical trial results. Blood. 2002;100(11):804.
7. Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12(11):1150-1160. (Pubitemid 44660857)
8. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107(4):1325-1331. (Pubitemid 43242365)
9. Noonan K, Matsui W, Serafini P, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 2005;65(5):2026-2034. (Pubitemid 40478633)
10. Fellowes VS, Rose JJ, Hakim FT, Hardy NM, Bishop MR. Pre-clinical development of allogeneic tumor-derived donor lymphocyte immunotherapy product. Annual Meeting of the International Society for Cellular Therapy, May 23-26, 2010. Philadelphia, PA.
11. CTEP. Common Terminology Criteria for Adverse Events (CTCAE v3.0). Rockville, MD: National Cancer Institute; 2006.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
13. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
14. Beatty GL, Smith JS, Reshef R, et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res. 2009;15(15):4944-4953.
15. Huang J, Khong HT, Dudley ME, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28(3):258-267. (Pubitemid 40593992)
16. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression inmelanoma patients receiving cell transfer therapy. J Immunol. 2005;175(10):7046-7052. (Pubitemid 41598952)
17. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812-1826.
18. Fozza C, Longinotti M. T-cell traffic jam in Hodgkin's Lymphoma: pathogenetic and therapeutic implications. Adv Hematol. 2011;2011:501659.